Literature DB >> 11300469

A decade in the life of tumor immunology.

O J Finn1, M T Lotze.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11300469

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


× No keyword cloud information.
  9 in total

Review 1.  The dawn of vaccines for cancer prevention.

Authors:  Olivera J Finn
Journal:  Nat Rev Immunol       Date:  2017-12-27       Impact factor: 53.106

Review 2.  Human tumor antigens, immunosurveillance, and cancer vaccines.

Authors:  Olivera J Finn
Journal:  Immunol Res       Date:  2006       Impact factor: 2.829

Review 3.  ELISpot for measuring human immune responses to vaccines.

Authors:  Meredith Slota; Jong-Baeck Lim; Yushe Dang; Mary L Disis
Journal:  Expert Rev Vaccines       Date:  2011-03       Impact factor: 5.217

4.  Phase I clinical trial of human vascular endothelial growth factor receptor 1 peptide vaccines for patients with metastatic renal cell carcinoma.

Authors:  K Yoshimura; T Minami; M Nozawa; H Uemura
Journal:  Br J Cancer       Date:  2013-03-07       Impact factor: 7.640

5.  The Granzyme B ELISPOT assay: an alternative to the 51Cr-release assay for monitoring cell-mediated cytotoxicity.

Authors:  Kimberly Shafer-Weaver; Thomas Sayers; Susan Strobl; Eric Derby; Tracy Ulderich; Michael Baseler; Anatoli Malyguine
Journal:  J Transl Med       Date:  2003-12-29       Impact factor: 5.531

6.  Evaluating the cytotoxicity of innate immune effector cells using the GrB ELISPOT assay.

Authors:  Kimberly A Shafer-Weaver; Thomas Sayers; Douglas B Kuhns; Susan L Strobl; Mark W Burkett; Michael Baseler; Anatoli Malyguine
Journal:  J Transl Med       Date:  2004-09-20       Impact factor: 5.531

7.  Detection of peptide-specific CTL-precursors in peripheral blood lymphocytes of cancer patients.

Authors:  Y Maeda; N Hida; F Niiya; K Katagiri; M Harada; H Yamana; T Kamura; M Takahashi; Y Sato; S Todo; K Itoh
Journal:  Br J Cancer       Date:  2002-09-23       Impact factor: 7.640

8.  A phase I trial of cytotoxic T-lymphocyte precursor-oriented peptide vaccines for colorectal carcinoma patients.

Authors:  Y Sato; Y Maeda; H Shomura; T Sasatomi; M Takahashi; Y Une; M Kondo; T Shinohara; N Hida; K Katagiri; K Sato; M Sato; A Yamada; H Yamana; M Harada; K Itoh; S Todo
Journal:  Br J Cancer       Date:  2004-04-05       Impact factor: 7.640

9.  Expression of the 5T4 oncofoetal antigen in renal cell carcinoma: a potential target for T-cell-based immunotherapy.

Authors:  R W Griffiths; D E Gilham; A Dangoor; V Ramani; N W Clarke; P L Stern; R E Hawkins
Journal:  Br J Cancer       Date:  2005-09-19       Impact factor: 7.640
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.